AOP Health announced new results on ropeginterferon alfa-2b (BESREMi®) from its clinical study CONTINUATION-PV in patients with polycythaemia vera (PV), a rare blood cancer. Professor Heinz Gisslinger
AOP Health Presents New Findings Regarding Consistent Hematologic Response of Patients With polycythaemia vera afp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from afp.com Daily Mail and Mail on Sunday newspapers.
AOP Health Presents New Findings Regarding Consistent Hematologic Response of Patients With polycythaemia vera streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ According to a study by Transparency Market Research, the global viral vector production market is expected to grow at a compound annual growth.
AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Health's CONTINUATION-PV study (Reference Kiladjian et al. ASH 2022) and the LOW-PV